Loading clinical trials...
Loading clinical trials...
Sigma-1 Receptors: A Novel Clinical Target in Fragile X Syndrome
Conditions
Interventions
18F-FTC-146
Locations
1
United States
Stanford University
Stanford, California, United States
Start Date
January 12, 2021
Primary Completion Date
June 1, 2022
Completion Date
June 1, 2022
Last Updated
November 15, 2022
NCT07439510
NCT06957054
Lead Sponsor
Guido A. Davidzon, MD, SM
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions